



ANNUAL REPORT

Freedom from Infectious Disease

2009



“Imagine a world free from the threat of infectious disease. We do.”

LOOKING AHEAD TO 2020

Our new shortened name, Seattle BioMed, is a reflection of what we do and who we are — a local leader in biomedical research whose discoveries will help save millions of lives worldwide.

Christoph Grundner, Ph.D.

As Seattle Biomedical Research Institute looks to the start of a new decade, the idea that new solutions could be possible by the end of the next decade is thrilling.

And thinking through the last 10 years, we've come so far — as an organization, as a global health community in the Pacific Northwest and as a world focused on the need to improve the health of all.

That reflection led us to take a look at our name — does it indicate what we do and who we are? The answer, after many conversations and hours of information gathering, is yes. And, while we found that people are familiar with our mission, we also learned our acronym, SBRI, was unmemorable. We were urged to celebrate Seattle as part of our name, as well as be clear that we are a biomedical research organization. So Seattle BioMed has been adopted as our new shortened name. It is a clear

reflection of the niche we fill and our leadership role in putting Seattle on the map as a nexus for global health.

While there are a number of great organizations filling in critical parts of the scientific pipeline, the pipeline would never yield results without discovery research and that's where we have proven success. The coming decade will allow us to build on that success by translating our discoveries to help save millions of lives.

Imagine the possibilities: Vaccines that could be the long-term solutions for deadly infectious diseases. Drugs that are smarter than the organisms that have figured out how to circumvent current therapies. Diagnostics that rapidly determine a disease so that treatment can begin immediately. Within the coming decade, all these things are possible.

Imagine a world free from the threat of infectious disease. We do.



COLLABORATION

With more than 100 collaborations with leading organizations throughout the U.S. and around the world, Seattle BioMed has powerful partnerships. Together, we can accomplish much more as we accelerate new solutions to fulfill our mission.

INTERNATIONAL

Astellas Pharma Inc., Japan
 Biomedical Primate Research Centre, The Netherlands
 Christian de Duve Institute of Cellular Pathology (ICP), Université Catholique de Louvain (UCL), Belgium
 Egerton University, Kenya
 Griffith University, Australia
 Guy's Hospital, U.K.
 Foundation for Innovative New Diagnostics (FIND), Switzerland
 INOVIO, Norway
 Institute of Parasitology, Czech Academy of Sciences, Czech Republic
 Institute of Protein Biochemistry, National Research Council, Italy
 International Center for Genetics and Biotechnology, India
 International Centre for Diarrheal Disease Research, Bangladesh
 Jawaharlal Nehru University, India
 London School of Hygiene and Tropical Medicine, U.K.
 McGill University, Canada
 Morogoro Regional Hospital, Tanzania
 Nanomics Biosystems Pty Ltd, Australia
 National Institute of Infectious Diseases, Japan
 National Institute for Medical Research, Tanzania
 National Institute of Public Health and the Environment, The Netherlands
 National Research Council, Canada
 Norwegian University of Science and Technology (NTNU), Norway
 Novartis Institute of Tropical Diseases, Singapore
 Response Biomedical Corporation, Canada
 Ruhr-Universität Bochum, Germany
 Sokoine University, Tanzania
 Pasteur Institute, France
 TriTryp Genome Consortium
 Tumaini University, Tanzania
 Universitätsklinikum Charité Berlin, Germany
 University of Antioquia, Colombia
 University of Buea, Cameroon
 University of Cambridge, U.K.
 University of Capetown, South Africa
 University of Copenhagen and Rigshospitalet, Denmark
 University of Dar es Salaam, Tanzania
 University of Dundee, Scotland, U.K.

University of Edinburgh, Scotland
 University of Glasgow, Scotland
 University of Heidelberg, Germany
 University of Nairobi, Kenya
 University of Otago, New Zealand
 Oxford University, U.K.
 University of Queensland, Australia
 University of the Ryukyus, Japan
 University of the Witwatersrand, Johannesburg, South Africa
 Universidade Federal de São Paulo, Escola Paulista de Medicina, UNIFESP-EPM, Brazil
 Vrije Universiteit, The Netherlands
 Walter and Eliza Hall Institute of Medical Research, Australia
 Wellcome Trust Sanger Institute, U.K.

UNITED STATES

Aaron Diamond AIDS Research Center
 Bill and Melinda Gates Foundation
 Blood Cell Storage, Inc.
 Boston University
 Brandeis University
 Broad Institute
 Brown University Medical School
 Buck Institute
 C3 Jian, Inc., Los Angeles
 California Institute for Medical Research
 California Institute of Technology
 California National Primate Research Center
 Centers for Disease Control & Prevention (CDC)
 Columbia University
 Cornell University
 Drexel University
 Duke University
 Fred Hutchinson Cancer Research Center
 Harborview Medical Center
 Harvard University
 ImmPORT Therapeutics, Inc.
 Indiana University
 Infectious Disease Research Institute
 Institute for Systems Biology
 Johns Hopkins University
 La Jolla Institute of Allergy and Immunology
 Los Alamos National Laboratory
 Merck Research Laboratories
 Microsoft Research
 National Institutes of Health
 New York University
 North Carolina State University
 Northwestern University
 Novartis
 Oregon Health & Science University
 Oregon National Primate Research Center
 Oregon State University
 PATH
 Pacific Northwest National Laboratory
 Portland Veterans Affairs Medical Center
 Rosetta/Merck Research Labs
 Saint Louis University
 Santa Clara Valley Medical Center
 Schering Plough Biopharma
 Scripps Research Institute
 Seattle Genetics
 Southwest National Primate Research Center, San Antonio
 Stanford University
 TB Control Program, Public Health - Seattle King County
 Texas A & M University
 Tulane National Primate Research Center
 Tulane University
 University of California, Berkeley
 University of California, Davis
 University of California, Los Angeles
 University of California, San Francisco
 University of Chicago
 University of Illinois, Chicago
 University of Iowa
 University of Massachusetts, Worcester
 University of Michigan
 University of Missouri
 University of Nebraska
 University of North Carolina
 University of Oklahoma
 University of Oregon
 University of Pennsylvania
 University of Pittsburgh
 University of Rochester
 University of San Diego
 University of Texas, San Antonio
 University of Virginia
 University of Washington
 U.S. Environmental Protection Agency
 Vanderbilt University
 J. Craig Ventner Institute
 Walter Reed Army Institute of Research
 Washington National Primate Research Center
 Yale University
 Yerkes National Primate Research Center, Atlanta

LETTER FROM THE PRESIDENT

“We relish the responsibility to play a lead role in forming partnerships that encourage the sharing of scientific knowledge in global health.”



2009 was a year of success for Seattle Biomedical Research Institute. This year, our scientists continued to grow and make research advances on multiple fronts. We transformed our building to accommodate trials of our live-attenuated malaria vaccine candidate and to meet technical requirements of our expanding tuberculosis program. We also now use a new short name “Seattle BioMed.”

Seattle BioMed is expanding and strengthening connections with people around the globe who are working on solutions to infectious disease. Our scientists and staff, who have never worked in isolation, have increased their working interactions with scientists, advocates, funders and policy makers elsewhere who are directed towards our common goal of saving lives and reducing suffering. These joint activities not only impact global health but also contribute to the regional biomedical research enterprise.

For example, the first Global Health Research Congress, which I had the honor of chairing, was held in conjunction with and was designed to complement the 2009 Pacific Health Summit which focused on tuberculosis. The Congress convened leading scientists and policymakers and provided a forum for hearing and discussing recent research advances and next directions. This illustrates how we can work together with others to assess the best approaches to infectious disease research. This important event will be repeated in 2011 when the Summit reconvenes in Seattle.

We at Seattle BioMed relish the opportunity and responsibility to play a lead role in forming partnerships that encourage the continual development and sharing of scientific knowledge in



global health. We have already made great advances in malaria research partnerships that could deliver an effective malaria vaccine in the very near future. You will also find Seattle BioMed leading and participating in meetings of the minds right here in Seattle and around the world. I hope you will follow us as we increase our research footprint, and I encourage you to connect with your own networks about the research underway in our labs. By partnering together, I believe we will soon celebrate life-saving breakthroughs in global health.

Kenneth Stuart, Ph.D.
President & Director

LETTER FROM THE BOARD CHAIR



Throughout our lives, we're often asked how we are connected with a person, group or a cause. I find that the important question is not how I *got* connected, but why I *stay* connected.

My first point of connection to Seattle BioMed came after hearing about the local research organization that had a promising malaria vaccine. I knew a few board members, but had very little information about the organization. I started to learn as much as I could and became impressed with the quality of the work and people.

What keeps me connected to this premier infectious disease institute? Well, the fact that Seattle BioMed is successful is a large part of it. Being connected to a growing organization

“These men and women welcome the challenge of the world's toughest diseases and are making great strides in translating their discoveries into new solutions.”

that is attacking unmet medical needs, especially those targeted toward the less fortunate, is not only exciting but also allows me to be part of an important solution.

During my career in the for-profit biotech sector, I never had the opportunity to be involved in advancing new solutions for underdeveloped markets. When you are motivated by profit, there is little sense in developing products for people that can't afford to pay. Unfortunate, but true. Being able to use my commercial experience to help Seattle BioMed translate its knowledge to drugs and vaccines that can serve people in need is the major reason for me to stay connected.

I also find that I'm inspired by my connection to the scientists of Seattle BioMed, the best and brightest in the world. These men and women welcome the challenge of the world's toughest diseases and are making great strides in translating their discoveries into new solutions. Read this report to find out more.

In 2010, we hope you'll get connected to Seattle BioMed and our vision of a world free from infectious disease. Join us for our annual Passport to Global Health Celebration, come to an event at Seattle BioMed or visit our labs. Go to seattlebiomed.org to find an opportunity that's right for you.

Todd Patrick
Board of Trustees Chair



THE POWER OF PARTNERSHIPS

Taking on Tuberculosis

Scientists, staff and supporters christened Seattle BioMed's new TB lab earlier this year. "Like baking, science is all about the right combination of ingredients—just like you helped put together the right ingredients for this lab," said Principal Investigator David Sherman, Ph.D., as he presented trustees Dean Allen and Marlyn Friedlander with his home-baked cake in appreciation of their fundraising efforts.

From a handful of scientists to a diverse team of 325—that's how much Seattle BioMed has grown since our founding three decades ago. Much of the Institute's growth is a direct result of successes in discovery research, but growth also happens as a result of powerful partnerships.

Making Introductions

As head of McKinstry Co., Dean Allen often says with a smile that he's "just a plumber," but his passion lies in global health. Allen, a Seattle BioMed trustee, is one of the Institute's earliest – and most passionate – advocates. He introduced Seattle BioMed to partners that helped develop our purpose-built research facility in the South Lake Union neighborhood.

But one of Allen's most influential partnerships has been with long-time friends Gilbert Scherer and Marlyn Friedlander, whom he introduced to

Seattle BioMed. Husband and wife team Scherer and Friedlander have both served as trustees, offering their expertise in communications, marketing, advocacy and development.

They joined forces to help the Institute launch several fundraising initiatives that accelerated our top infectious disease research programs. Allen and Friedlander teamed up to co-chair the Institute's first Passport to Global Health Celebration, an awareness-building event that has proved wildly successful, during its five-year history raising more than \$2 million and educating well over 3,000 people about infectious disease research.

An Alliance for TB Research

When Seattle BioMed turned a focus toward building a world-class tuberculosis (TB) program, Allen and Friedlander again raised their hands to champion the cause. They met with Tuberculosis Program Principal Investigator David Sherman, Ph.D., to plan a new campaign to extend Seattle BioMed's TB research footprint.

Tuberculosis is one of the longest reigning diseases in history; nearly two million people die from TB every year, and one in three people carry the TB bacterium in their lungs. With a little advocacy and perseverance, Allen, Friedlander and Sherman believed they could raise funds to build a specialized TB lab and move research discoveries toward new TB treatments.

To put Seattle BioMed on the map in terms of its TB research, Sherman played the role of the teacher, educating everyone Allen and Friedlander introduced to him about the basic biology of the disease. "Our research program is focused on tackling the tough problems of TB biology," he said. "By uncovering the strategy that the TB bacterium uses for long-term survival, we can gain insight into developing faster-acting, more effective drugs."

While Sherman explained the science, Allen encouraged the community to believe in Seattle BioMed's success. "In the past, we've celebrated the huge accomplishments of our malaria program," said Allen. "That same success is possible in TB."

Friedlander focused on the urgency to find new TB drug therapies. "Someone dies from TB every 20 seconds, but there hasn't been a new TB drug in over 40 years," she said. "We have the ability to change this if we focus on enabling scientists to accelerate their research."

Adding More Partners

Together, the three TB champions packed a powerful punch. Under their campaign leadership, Seattle BioMed secured another influential partner: the Paul G. Allen Family Foundation, which provided a \$5 million challenge grant. This in turn brought in generous gifts from other foundations and private donors. These gifts enabled the construction of a new, state-of-the-art TB laboratory, which is now fully functioning on the Institute's second floor.

The TB campaign paid off not only in square footage, but also in new talent. Christoph Grundner, Ph.D., an up-and-coming scientist from the University of California, Berkeley, recently joined Seattle BioMed as its newest principal investigator.

"The new TB lab facility was one of the key reasons I decided to come to Seattle BioMed," Grundner said. "And, it's wonderful to work alongside David on cutting-edge TB research."

Sherman and Grundner are now partnering to better understand TB virulence and learn more about immunity and infection. "Despite being one of the world's most prevalent pathogens, *Mycobacterium tuberculosis* – the bacterium that causes TB – is still a puzzle," Sherman explains. "Our ultimate goal is to translate our research findings into better therapies for tuberculosis."



TB gains strength as new strains become resistant to current treatments.



Dean Allen leads fundraising for Seattle BioMed's new TB lab.



David Sherman, Ph.D., presenting Dean Allen and Marlyn Friedlander with a gift of appreciation.



Sherman welcomes new principal investigator Christoph Grundner, Ph.D. (left).

“The new TB lab facility was one of the key reasons I decided to come to Seattle BioMed.”

“No man is an island.” This often repeated quote definitely holds true in the world of research where scientists from around the world connect to accelerate new solutions for age-old infectious diseases. The power of Seattle BioMed’s partnerships is moving a promising malaria vaccine forward, while building much-needed clinical testing capacity for the malaria research community for the future.

“Back to the future” is often the way Seattle BioMed’s Stefan Kappe, Ph.D., describes how he developed a malaria vaccine candidate that is in human clinical trials this year. This genetically attenuated parasite (GAP) vaccine, created by deletion of two genes that stop the malaria parasite during liver infection thereby eliminating clinical disease, has proven 100 percent successful, 100 percent of the time in a mouse model. With funding provided by a Grand Challenges in Global Health award, the vaccine candidate is now moving “from mice to men,” Kappe says with a smile.

Mind the GAP

The GAP approach builds on knowledge from several decades ago, when scientists proved that irradiated malaria parasites provide protection against subsequent malaria infection in animal models and humans. “From this, we knew there were possibilities to attack the liver stage of the disease,” Kappe explained. “But, we believe genetic engineering of the parasite is the answer as it provides consistent, reproducible results.” This approach

to vaccine development – using a weakened form of the whole organism that causes a particular disease – has proven successful in eradicating smallpox and controlling diseases such as flu or polio.

While Kappe is the driving force behind the idea, the GAP vaccine project relies on expertise from strong partners around the world. Scientists at the Walter & Eliza Hall Institute were instrumental in replicating the GAP vaccine candidate to the form suitable for human testing. The Walter Reed Army Institute of Research (WRAIR), with a long and successful history of safely testing malaria vaccines in humans, is conducting the initial clinical trial of Kappe’s vaccine. “Without our collaborators, our vaccine wouldn’t be this far down the pipeline,” Kappe said. “And, with a problem the size of malaria, time matters. The faster we can accelerate a new solution, the more lives we’ll save.”

Using Mosquitoes

The expertise and scale of Seattle BioMed’s malaria program, along with its scientists’ drive to translate discoveries into solutions, have led to other partnerships. And having an insectary – a lab for growing malaria infected mosquitoes – on site is something unique we have to offer our partners.

Seattle BioMed is now home to the Malaria Clinical Trials Center (MCTC) – the fourth such facility in the world – which will accelerate

the clinical assessment of malaria drug and vaccine candidates by conducting malaria human challenge studies. The PATH Malaria Vaccine Initiative (MVI) provided funding to build the Human Challenge Center component of the MCTC (which has received other federal and private funding), while WRAIR is providing guidance, training and malaria strains for the center. Researchers at the University of Washington will provide additional clinical and safety oversight.

Moving Vaccines Forward

“Early phase clinical testing of candidate malaria vaccines can provide researchers with valuable information to decide whether or not to move a potential vaccine forward,” explained Angela Talley, M.D., Clinical Trials Lead Investigator of the MCTC. “And, having the right partners bringing critical expertise is absolutely essential to standing up this facility. Likewise, expanding the worldwide capacity for conducting these types of studies benefits all our partners and the malaria community.”



“Supporting the development of an additional facility for testing malaria vaccine approaches is another way that MVI is helping to accelerate vaccine development,” says Christian Loucq, M.D., Director of MVI. “We look forward to the day when the Seattle BioMed facility – as well as those in other locations – is fully booked with trials. This would be real progress.”

COLLABORATING ON MALARIA VACCINES



Angela Talley, M.D.

PARTNERING TO ATTACK CO-INFECTION



“We have so much expertise in both HIV and TB, and the need is so great, that it only made sense to study how those two infections work together.”

In the developing world, people with HIV have a number of things to be concerned with – lack of treatment, a compromised immune system and social stigma are just the start of a long list. But now, HIV patients have another deadly concern: tuberculosis (TB).

When HIV and TB form a partnership, the results are devastating. According to the World Health Organization, TB is a leading cause of HIV-related deaths worldwide.

To combat this deadly duo, researchers at Seattle BioMed have formed some new partnerships of their own. Don Sodora, Ph.D., a principal investigator in Seattle BioMed's Viral Vaccines Program with a focus on HIV infections, has long been interested in ways to connect scientifically with his colleagues who have a different disease focus than he does.

Links Between HIV and TB

“We have so much expertise in both HIV and TB, and the need is so great, that it only made sense to study how those two infections work together,” Sodora said. “In the developing world, it's not uncommon to have one or more infections. And, co-infections can dramatically change our research findings as well as the disease course in these patients, so we need to understand how diseases like TB and HIV impact one another.”

Sodora received an Innovations Grant, funded with gifts from donors who give to Seattle BioMed's Breakthrough Fund as well as at the Passport to Global Health Celebration, to get his study off the ground. As a collaborative effort with Leo Stamatatos, Ph.D., director of Seattle BioMed's Viral Vaccines program, and TB Principal Investigator David Sherman, Ph.D., he'll take a look at HIV and TB co-infection of macrophages, which are large white blood cells that help the body fight off infections by ingesting the disease-causing organism. HIV can infect and kill macrophages.

Seed Grant Provides Data

“From this seed grant, we hope to generate enough data to write a larger grant proposal to determine how HIV infected macrophages defend themselves against a live tuberculosis infection,” he said. “Understanding how HIV infection impacts macrophage function is an important step toward developing new therapeutic approaches to reduce the number of TB-associated deaths.”

Sodora hopes to expand into other related infections. Last fall, he organized a symposium that drew well more than 100 researchers from across the U.S. to discuss a variety of co-infections including HIV and TB as well as other infectious agents associated with co-infections such as parasitic worms, malaria and pathogenic yeast infections.

Seattle BioMed's Ted White, Ph.D., director of the Emerging Infections Program, sees great potential. White's research program is focused on pathogenic yeasts including *Candida albicans*, the causative agent of oral thrush (candidiasis) in HIV-infected patients. “Virtually all of the diseases studied at Seattle BioMed can be linked as co-infections,” he said. “There's much to be learned by forming these connections among our fellow researchers and collaborators.”



Zane Kraft mentors intern Jacqueline Benthuisen.

The “eureka” moment – it’s what scientists strive for. Jacqueline Benthuisen got her first taste of it during her Global Health Internship at Seattle BioMed.

“I love working in the labs. Some might think it’s tedious,” Benthuisen said about doing experiments over and over, looking for one success out of hundreds of trials. “But with a little patience, the ‘Yes! I finally got it!’ moment makes it all worthwhile.”

Benthuisen was one of three college students awarded Seattle BioMed’s competitive, highly sought-after Global

Health Internships in 2009. These summer-long training opportunities, funded by gifts to Seattle BioMed’s Breakthrough Fund, connect Institute scientists with students eager to break into infectious disease research.

Teachers at Heart

Benthuisen trained with Zane Kraft, a research technician in one of Seattle BioMed’s HIV labs. “This was my third year mentoring a Global Health Intern,” Kraft explained, “and the experience never gets old for me. I’m glad we have a policy of welcoming students into our labs to train alongside us – it’s rewarding.”

From Kraft’s perspective, interns bring a welcome new energy into the lab environment. “Scientists are really teachers at heart, so it’s great to share information with students who get excited about our work,” he said.

Beyond the Classroom

A senior at University of Washington, Benthuisen has spent much of her time at college working with fruit flies and genetics labs. “My internship at Seattle BioMed has been a great opportunity to study infectious disease and immunology and to practice new research techniques.”

Although Benthuisen has completed her internship, she’s already found her way back to Seattle BioMed, working part time in the HIV lab while earning school credit. “I’m thrilled that I can continue learning here—it’s a welcoming place where my colleagues don’t mind answering all my questions, or helping me report my research findings and supporting me as I advance my studies.”

The Breakthrough Fund

Through Seattle BioMed’s Breakthrough Fund, you can play a role in sponsoring training programs that enable college students to become tomorrow’s leading scientists. Visit seattlebiomed.org to make your Breakthrough Fund gift.



Addie Baker with children in Benin.

Shadowed doctors in Ecuador. Sent a thousand pounds of school supplies to children in Iraq. Published pathogen research findings in a scientific journal. These are just a handful of milestones Washington students have achieved since graduating from Seattle BioMed’s BioQuest Academy—a science education program for high school juniors. More than 160 teens have completed the Academy, and although there’s no way to predict the magnitude of success their futures hold, they’re well on their way toward making a global impact. And, maybe some of them will make their way back to Seattle BioMed, which trains budding scientists from high school through the post-doctoral level.

Bringing Healthcare to Communities in Need

For 2005 BioQuest Academy graduate Addie Baker, a passion for health has taken her from BioQuest’s learning lab all the way to Africa. Currently a senior in Gonzaga University’s nursing program, Baker spent two weeks

during summer break learning about health care practices in the developing country of Benin. There, she used her health and science skills to help build health care clinics and sanitation programs for the men, women and children battling health disparities in Benin’s poorest communities.

Recalling her experience abroad, Baker remembers that “the people of Benin were incredible, so warm and trusting, even though we were strangers entering their homes.”

For Baker and many other BioQuest students, sharing that kind of compassion with neighbors near and far is what global health is all about. “I saw so many smiles among the suffering and poverty-stricken people of Benin,” she said. “Their faces give me hope.”

Hope for the Next Generation

Baker’s photographs from Benin, like the one pictured here, capture the optimism of people who are counting

BioQuest ACADEMY

Connecting Students to the World

on the next generation of global health leaders, like her and her BioQuest Academy classmates, to help them achieve healthy lives.

“In the future I would love to go back to Benin, or travel to different countries, armed with the knowledge and skills I’ve learned from BioQuest and nursing school, and give back everything I can,” said Baker. Theresa Britschgi, director of the BioQuest program, is always pleased to hear how former students are doing.

“It’s clear from her photographs that Addie has a special connection with children,” she said. “How appropriate that Addie plans to pursue her nursing career with a focus on pediatric care.”

Seattle BioMed’s BioQuest science education program, supported in part by a Science Education Partnership Award (SEPA) from the National Center for Research Resources, a part of the National Institutes of Health, enables today’s youth to think critically, learn innovatively and act compassionately to become tomorrow’s scientific leaders and global health advocates.

To read more stories about BioQuest graduates connecting with the world, visit seattlebiomed.org.



FOLLOWING IN FOOTSTEPS: Mentoring Tomorrow’s Scientific Leaders

Principal Investigators

Jerry Cangelosi, Ph.D., Affiliate Member
 Nick Crispe, M.D., Ph.D., Full Member
 Michal Fried, Ph.D., Assistant Member
 Malcolm Gardner, Ph.D., Full Member
 Christoph Grundner, Ph.D., Assistant Member
 Helen Horton, Ph.D., Associate Member
 Stefan Kappe, Ph.D., Associate Member
 Peter Myler, Ph.D., Full Member
 Marilyn Parsons, Ph.D., Full Member, Director of Science Operations
 David Sherman, Ph.D., Full Member
 Joe Smith, Ph.D., Interim Program Director & Associate Member
 Don Sodora, Ph.D., Associate Member
 Leo Stamatatos, Ph.D., Program Director & Full Member
 Ken Stuart, Ph.D., President and Director
 Ruobing Wang, M.D., Ph.D., Associate Member
 Ted White, Ph.D., Program Director & Full Member

Senior & Staff Scientists

Jason Carnes, Ph.D.
 Amy DeRocher, Ph.D.
 Sean Gray, Ph.D.
 Bryan C. Jensen, Ph.D.
 Sebastian Mikolajczak, Ph.D.
 Andrew V. Oleinikov, Ph.D.
 Aswini Panigrahi, Ph.D.
 Tige Rustad, Ph.D.
 Noah Sather, Ph.D.
 Angela Talley, M.D., Lead Trials Investigator
 Ashley Vaughan, Ph.D.
 Marissa Vignali, Ph.D.

Visiting Scientist

Patrick Duffy, M.D.

Affiliate Scientists

Jean Feagin, Ph.D.
 Nancy Haigwood, Ph.D.
 Rentala Madhubala, Ph.D.
 Achim Schnauffer, Ph.D.
 Lorenz von Seidlein, Ph.D.
 Alice Tarun, Ph.D.

Management

Tom Blackwell, Director of Information Technology
 Randy Hassler, Vice President of Operations & Finance
 Kent Irwin, Director of Facilities
 Michael Podlin, Vice President of Institutional Advancement
 Lee Schoenstrup, Director of Communications
 Ken Stuart, Ph.D., President and Director
 Jeanine Willis, Director of Human Resources
 Lynn Zimmerman, Director of Finance

BioQuest

Theresa Britschgi, BioQuest Director

American Medical Association Foundation
 American Society of Microbiology
 Antigen Discovery, Inc.
 Bill & Melinda Gates Foundation
 Burroughs Wellcome Fund
 The Doctor Ralph and Marian Falk Medical Research Trust
 Ellison Medical Foundation
 Eunice Kennedy Shriver National Institute of Child Health and Human Development
 Fogarty International Center
 Foundation for Innovative New Diagnostics (FIND)
 Foundation for the National Institutes of Health
 Fred Hutchinson Cancer Research Center
 Grace and Harold Sewell Memorial Fund, Inc.
 The Harvest Foundation
 Imperial College of London
 Infectious Disease Research Institute
 Medicines for Malaria Venture
 The Medtronic Foundation
 Merck & Co., Inc.
 National Institutes of Health
 National Center for Research Resources
 National Heart, Lung, and Blood Institute
 National Institute of Allergy and Infectious Diseases
 National Institute of Dental and Craniofacial Research
 National Institute of Diabetes and Digestive and Kidney Diseases
 National Institute of General Medical Sciences
 National Institute of Neurological Disorders and Stroke
 PATH
 Paul G. Allen Family Foundation
 Rhode Island Hospital
 Special Libraries Association
 Stanford University
 U.S. Army Medical Research and Materiel Command
 U.S. Environmental Protection Agency
 United States-Israel Binational Science Foundation
 University of Pennsylvania
 University of Washington
 Washington Global Health Alliance

Emeritus Board

Alan Alhadeff
 Margaret Allen, M.D.
 Ellsworth Alvord Jr., M.D.
 Mark Benjamin, Sc.D.
 J. Paul Blake
 Carol Bryan
 Vincent Bryan, M.D.
 Robert Bunting
 Alice Burgess
 John Creighton, Esq.
 Andrew Dale
 Nancy Duncan
 Janet Lane Eaton
 Steve Gillis, Ph.D.
 Harris Hoffman
 John King
 Alvin Kwiram, Ph.D.
 Carol Lewis
 Jilan Liu, M.D., M.H.A.
 Katherine M. Lombardo
 Gary McGlocklin
 Peter Miller, J.D.
 Susan Morgensztern
 Peggy Morrow
 Thomas O'Rourke
 Judy Pigott
 Thomas Ranken
 Chuck Robertson
 Gilbert Scherer
 Ezra Teshome
 Usha Varanasi, Ph.D.
 Tom Waldron
 Rick Weller, M.D., D.T.M.& H.
 Michelle A. Williams, Sc.D.
 Mary Williamson
 James Woods, Ph.D.
 Jeffrey Wortley
 Louis Yaseen

Dean Allen
 Chief Executive Officer, McKinstry Co.
 Rosemary Barker Aragon
Communications Advisory Group Chair
 Executive Director, Pacific Hospital Preservation & Development Authority
 Jane A. Biddle, Ph.D., *BioQuest Advisory Group Chair*
 Technology Transfer Consultant
 Gregg Blodgett
 Chief Financial Officer, Twisted Pair Solutions
 Joe Cerrell
 Director, Global Health Advocacy,
 Bill & Melinda Gates Foundation
 Maud Daudon* *Immediate Past Chair*
 CEO & President, Seattle-Northwest Securities Corporation
 James Davie
 President & Director, Blood Cell Storage Inc.
 Bruce Easter
 Community Volunteer
 Marilyn Friedlander* *Development Committee Chair*
 Community Volunteer
 Jane Hedreen
 Passport Event Committee Co-Chair
 Owner, Flora & Henri
 Darryl Johnson* *Secretary*
 Former U.S. Ambassador to Thailand & Lithuania
 James A. Johnson
 Executive Vice President, CFO & Treasurer, ZymoGenetics, Inc.
 Alan Levy, Ph.D.
 Venture Partner, Medical Devices
 Frazier Healthcare Ventures
 Terrence R. Meersman
 Vice Chair, Talaris Research Institute
 Trevor Moody* *Vice Chair*
 General Partner, Frazier Healthcare Ventures
 Todd Patrick* *Chair*
 Community Volunteer
 Gloria Pfeif*
 Independent Consultant
 Christopher H. Porter, Ph.D.* *Business Strategy Committee Chair*
 President, Medical Genesis
 Erick Rabins
 Chief Business Development Officer & Senior Vice President,
 Strategic Affairs, C3-Jian, Inc.
 Greg Simon, J.D.
 Senior Vice President, Worldwide Policy, Pfizer, Inc.
 Mike Stull* *Treasurer & Finance & Audit Committee Chair*
 Chief Financial Officer, Clarisonic
 Bonnie Towne
 Community Volunteer
 Moya Vazquez* *Board Operations Committee Chair*
 Community Volunteer

* Executive Committee Member

Council of Scientific Advisors


Ben Shapiro, M.D., *Chair*
 Director of Research, Retired, Merck Research Laboratories
 Rafi Ahmed, Ph.D.
 Director, Emory Vaccine Center, Emory University
 Clifton E. Barry, III, Ph.D.
 Senior Investigator, Chief, Tuberculosis Research Section,
 NIAID, NIH
 John W. Shiver, Ph.D.
 Vice President, Worldwide Basic Research Franchise Head,
 Vaccines Merck Research Laboratories
 Thomas E. Wellems, M.D., Ph.D.
 Chief, Malaria Genetics Section, NIAID, NIH

Board of Trustees as of September 30, 2009.


SELECT FINANCIAL DATA

Fiscal years ending June 30 (dollars in thousands)


Revenue & Support



Total Net Assets



Budget by Scientific Program Area



Statements of Financial Position

	2009	2008
Cash & investments	\$23,194,705	\$20,889,703
Pledges receivable	\$1,874,506	\$750,480
Other assets	\$5,717,821	\$6,957,120
Property and equipment	\$10,691,336	\$9,037,157
Total Assets	\$41,478,368	\$37,634,460
Accounts payable and accrued expenses	\$5,848,727	\$3,641,238
Advances and deferred obligations	\$10,036,088	\$8,964,742
Capital project debt	\$4,404,992	\$5,423,158
Total Liabilities	\$20,289,807	\$18,029,138
Total Net Assets	\$21,188,561	\$19,605,322

Statements of Activities

	2009	2008
Support and Revenue		
Government Grants	\$16,182,487	\$14,950,866
Private Grants	\$22,850,761	\$18,967,982
Contributions	\$4,209,148	\$5,036,931
Educational Program	\$332,914	\$228,516
Investment and other income	\$2,560,332	\$1,649,498
Total Support and Revenue	\$46,135,642	\$40,833,793
Expenses		
Research program	\$38,687,302	\$34,775,224
Educational program	\$980,808	\$232,238
Management and administrative	\$4,189,915	\$4,178,996
Fundraising	\$586,624	\$458,660
Total Expenses	\$44,444,649	\$39,645,118
Increase in Net Assets	\$1,690,993	\$1,188,675

Audited statements available upon request. Please email connect@seattlebiomed.org.

HONOR ROLL

Collaborations with scientists, research organizations and policy makers have enabled Seattle BioMed to accomplish innovative advances in infectious disease research. But these entities make up only a fraction of the partnerships at the core of our work. Many of our most valuable relationships are with members of our community – like you – who contribute time, money and voices, placing power behind our mission to improve global health.

Individuals, foundations and corporations who share our vision help us bridge connections from the Seattle community to people around the world. Support through private contributions enables Seattle BioMed to expand on our research programs, recruit more bright scientists and form powerful alliances to advocate our mission.

We invite you to play a role in changing the health of the world. With your support, your advocacy and – most importantly – your partnership, we will realize a world where people are healthy and filled with hope.



Founder's Circle

\$1,000,000+

The Paul G. Allen Family Foundation
Bill & Melinda Gates Foundation

\$500,000+

M.J. Murdock Charitable Trust

\$100,000+

Dean & Vicki Allen/McKinstry Co. Charitable Foundation
The Doctor Ralph and Marian Falk Medical Research Trust
Silver Family Foundation

\$50,000+

Cuyama Foundation
Lease Crutcher Lewis Charles Simonyi Fund for Arts and Sciences

\$25,000+

Byron & Alice Lockwood Foundation
Gilbert Scherer & Marilyn Friedlander

\$10,000+

Anonymous
Jane A. Biddle, Ph.D. & Kenneth B. Seamon, Ph.D.
Bruce & Ann Blume EC Company
Barry & JoAnn Forman KeyBank National Association
Jerome M. Kobacker Charities Foundation
Carol Lewis & Tom Byers
Gloria Pfeif
Christopher & Kathryn Porter
The Seattle Foundation
The Teamtrio Fund, In Memory of David Clemetson
Moya Vazquez
We Work for Health

Pacesetters' Circle

\$5,000+

Amgen, Inc.
Anonymous
Kevin & Patrice Auld BNBuilders, Inc.
Cave B Estate Winery
Maud & Marc Daudon Firland Foundation
Frazier Family Foundation
David & Amy Fulton
Gilead Sciences, Inc.
Gray Family Fund of The Oregon Community Foundation
Racha & Wassef Haroun
Richard & Elizabeth Hedreen
James & Holly Johnson
Craig & Danna Kinzer
Mark Malamud & Susan Hautala
Merit Research
Trevor J. Moody & Laura Hernon
Judy Pigott
Wendy & Bill Rabel
Raj & Dilu Shah
David Thyer & Jane Hedreen
Vulcan Inc.
Washington State LASER
The Adam J. Weissman Foundation
Wells Fargo Insurance Services Northwest, Inc.

\$2,500+

Alexandria Real Estate Equities Inc.
Mari Anderson & Terry Green
BioMed Realty Trust, Inc.
Bert Green & Alexandra Brookshire
Vince & Carol Bryan
Clete & Bronwen Casper
Clark Nuber, PS
ClearPoint, LLC
Bruce Easter & Cynthia Faubion
Matt Griffin & Evelyne Rozner
Randy & Melanie Hassler
Mike & Liz Hilton
Ashley Hulsey & Marc Kittner
Invitrogen Life Technologies
Johnson Barrow, Inc.
The Lucky Seven Foundation
Medtronic Foundation
Todd & Julie Patrick
Petritz Strategic Group, Inc.
Michael Podlin
Bill Pope & Teresa Castner
Sparling
Drs. Ken Stuart & Julie McElrath
John & Teresa Tippet
Bonnie & Jim Towne
VLST Corporation
Washington Biotechnology & Biomedical Association
Ted White, Ph.D.
Jeanine Willis & Eric Freyberg
Wilson Sonsini
Goodrich & Rosati
Mariann & Kirk Zylstra
ZymoGenetics, Inc.
Bill & Janet Adamucci
Ellsworth & Nancy Alvord
Lisa & Michael Anderson
Robert S. Angel
Anonymous (5)
Perry & Christine Atkins
Tom Barwick
Kristin & Steven Beaulieu
Tom Blackwell
Jane & Gregg Blodgett
Edgar & Elisabeth Bottler Charitable Trust
Stan & Alice Burgess
Paul Carter
Joe & Sara Cerrell
Sally Collins & Chris Warth
Guy & Becca Conversano
Paul R. Cressman, Jr.
Scott & Louisa David
James & Sarah Davie
Mark & Christina Dawson, in memory of Dr. John H. Dawson
Melissa Dery
Nathan & Lisa Every
Theresa Fenton & Marc Lodge
Carolynn & Hal Ferris
Greg & Shalisan Foster
Kerry Fowler & Jan Gray
Dennis & Cindy Fulton
Saul Gamoran & Gurline Baptiste
Cezanne Garcia & David Grossman

Malcolm J. Gardner & Ruobing Wang
Cynthia Hartwig & Tom Booster
Hudson Bay Insulation
Julie Humling
Susan Hutchison
Peter & Sally Jarvis
Darryl & Kathleen Johnson
Gregg & Nancy Johnson
Pam & Kim Kaiser
Stefan Kappe & Dasha Li
Russ & Gretchen Keithly
Hans & Kelly Kemp
Kathleen Grant
Khosrowshahi
Joseph King & Whitney McCleary
Michael Kirschner
Josh LaBelle & Colleen Seffernick
Sharon Lee
Alan & Sharon Levy
Don Lewis
Ron & Robyn Lewis
Roy & Susan Mann
Dennis McLean & Bonnie Berk
Libby & Steve Miller
Peter Miller & Jean Johnson
Susan & Isaac Morgensztern
Brant Murdock
Shirley & David Newell
PATH
Setareh Palazzo
Marilyn Parsons
Lynn Perkins
Anne Pfeif
Patricia Pfeif
Mary Pigott
William Pope
Paul & Julie Pottinger
Regina Rabinovich, Ph.D.
Gordon & Gretchen Raine
Robert & Virginia Rausch
Kris Richey
The Reuben B. Robertson Foundation
Lawrence J. Roseman
James & Joy Roush
Schultz Miller
Gerard & Jody Schwarz
Carrie & Chad Schwitters
Sellen Construction
Christian Shevchenko
Speckman Law Group
Leo Stamatatos & Tina de Jong
Margaret & Hunt Stockwell
Jairus & Winnie Stratton
Bob & Katie Strong
Richard & Jennifer Swank

Supporters

\$500+

Eric Akines & Mike Doherty
Ellsworth & Eve Alvord
Anonymous (4)
Rosemary Barker Aragon
Bob & Clodagh Ash
Marisa Bavand
Connie Bechtel
Rena & Dana Behar
J. Paul & Robin M. Blake
Ann Bradford & Geoff Patterson
Kristi Branch & James Moore
Sam & Alicia Brasch
Evan Brown
Kim & Norm Brown
Fred Buckner
Tom & Claudia Campanile
Bruce & Jean Carter
Brad & Judy Chase
Robert & Kristina Clawson
Tom & Lisa Cohen
Ken & Sharon Coleman
CollinsWoerman
Earl & Anita Davie
Steve Davis & Bob Evans
Beth & Marc Droppert
Gordon & Susan Empey
Judy Fenyl-Melody & David Melody
Robert & Deborah Fleming
Mark Gardner
William & Mimi H. Gates, Sr.
Grund Painting
Lew Guerrette
Randall & Stefanie Hargreaves
Herd Freed Hartz
Helen Horton & Donald Carter

Richard & Andrea Hutton
Kent & Louise Irwin
Elizabeth James
Gerry Johnson & Linda Larson
Daniel Kress & Patricia Glick
Steve Kutz & Courtney Womack
Cheryl Lawrence
Stewart & Deby MacLeod
Candy Marshall
George & Beverly Martin
Tim McBride
Mary Jo & Marty Mehl
The MillerHull Partnership
Nicole & Robert Mooney
Steve & Thanne Moore
Laura & Loren Mork
Colin & Martha Moseley
Ralph Munro
Peter Myler & Alexa Allen
Shirley Naganawa & Gary Kawasaki
James O'Brien
H. Stewart Parker
Gwendolyn Payton & John Neelman
Prairie Foundation
Erick & Marta Rabins & Family
SABArchitects, Inc.
Will & Lee Schoentrup
Walter & Patricia Shea
Suzanne Shema & Bruce Schwarze
David Sherman, Ph.D.
Genie Sheth
Todd & Carolyn Simpson
Jeff Sloan
Scott Smedsrud
Ann Speckman
Dr. Andy & JoAnn Stergachis
Jeff & Annie Strain
Kristin Stred & Terry Prether
Sandhya Subramanian
Dr. George & Virginia Thomas
Preston Thompson
Luke Timmerman & Tracy Cutchlow
Steve & Karen Van Til
Greg & Vandana Slatter
Usha & S. Rao Varanasi
Maria D. Vasilakis, DMD
J. Tayloe Washburn & Deborah Winter
Elizabeth Weber
Tad Whiteside
Marion Woodfield & Marc Weinberg

\$250+

Benjamin O. & Joan Abe
Clif Alferness
Bruce & Joann Amundson
Michelle Anderson & Paul Olivier
Anonymous (7)
Jim Beers
Jean Berry
Karen Blochlinger
Gary & Jeannie Bodenstab
Lisa & Dirk Brandenburg
David Brenner
Robert & Theresa Britschgi
John Brooks
Maureen & Joe Brotherton
Ron Brun & Jeanne Olson
Kristin & Troy Buckley
Larry & Maggie T. Burke
Erik Busse
Mark Callaghan
Ray Calvert & Mim Turnbull
Jerry Cangelosi, Ph.D. & Gemma Borg
Peter Carpenter
Cascade Door & Hardware
Andrew Casper
Bobbi Chamberlin & Don Shifrin
Marcus & Sheila Charles
Dawn A. Clark
Dean & Susan Clark
Rachelle Cohen
Anita & Raymond Connell
Gregory Demopoulos
Div. 9 Flooring
Dr. Marcia Durfee
Steve Eirschele
Tom & Joanne Erlandson
Dr. Carl & Bonnieclare Erling
Paul Farmer
Jean E. Feagin, Ph.D.
Barbara Feasey
Kathleen Fowler
Tim Girvin
Leo Greenawalt
Ann Grodnik & Kyle Nagle
Christoph Grundner, Ph.D.
Douglas Haas & Helena Hilinga-Haas
Julianne Haase
Leslie Haeger
Joe & Denise Harris
Glenn & Harriet Hartquist

Toni & Michael Hatzakis, Jr.
Hamilton Hazlehurst & Pam Bekins
Chris Henderson & Megan Hirsh
Maggie Ho
Dave & Danielle Holmes
Brian Horman
John Howell & Claire Powers
David Humphries & Michelle McCarthy
Lee Huntsman
Janet & Bernie Jacobs
Debra Jarvis & Wes Vanvoorhis
Tracy Johannsen
Mary Johnson
Karen Jones
David & Anita Kaplan
Kennedy Associates
Robert Kirkman & Gakyung Chung
Susan Lammers & Walter Euyang
Steve & Katerina Lamola
Peter & Melba Lancaster
Dan Laster
Alice Lin
Tracy P. Lumsden
Sara Magee
Susannah Malarkey
Dave & Carrie McKeague
Cale McPherson
Terry Meersman & Carmen de la Hoz
Scott & Melissa Milburn
Tracy Mitchell
Peggy Morrow
Jennifer & Mikael Mortensen
Eileen & Barry Murphy
Ryan & Natascha Murphy
Elaine Nonneman
Nyhush Communications
Melissa Valdez O'Connor
James K. O'Halloran
PML Microbiologicals, Inc.
David & Julie Park
Tom Paulson
Gordon & Elizabeth W. Perkin
Isabelle Phan
Arvadin Phukan

Sara Pratt
Sally Quy
Mary Rennekamp
Kim Richter
Brenda Rodgers
Scott & Kerry Rosenkranz
Stephen Rothrock & Tessa Keating
Chris Russell
Susan Scanlan
Jill Scheuermann
Achim Schnauffer
Keith & Jennifer Schorsch
Peter & Mary Schroeder
Kavita Shah
Andrew C. Shawber
Carol Sibley, Ph.D.
Dorothy L. Simpson
Joseph & Leia Smith
Don Sodora, Ph.D.
Dr. Otto H. Spoerl
Amanda & Brent Spraker
Helen Stusser
Tonya Swick & Patty Grossbard
Jesse & Lilly Tam
David & Laura Tinker
George Tokiwa & Michele Cleary
Kelli Trosvig
Dave & Carrie McKean
David Tutt
Kirsten Vadheim & John Goodfellow
Jeff & Nancy Vehrs
Lisa Verhovek
Doug & Stacey Waddell
Jennifer Walsh & Richard Fisher
Lori Ward
Kathy Wehle & Theresa Haynie
Joshua Weinhacht
Katherine Weybright
Adam, Sarah & Brooklyn Wille
Marcia Williams
Oly Wise
Max Witter & Marcia Johnson Witter
Chris & Cary Young
Jennifer Smith-Yuen & Anson Yuen
Yang Zhang
Lynn Zimmerman & Jim Benbow

The 2008-2009 Honor Roll includes new pledges, outright gifts of cash and stock, pledge payments, and in-kind donations received from July 1, 2008 through June 30, 2009. Donors of \$1,000 and above are listed on the donor wall at Seattle Biomedical Research Institute.

6/30/2009

Each of our donors is important to us. Please notify elli.koskella@sbrl.org of any omissions or errors.

MISSION

Every day, we strive to eliminate the most devastating infectious diseases in the world.

VISION

We envision a world where people live free from the threat of infectious disease.

ABOUT SEATTLE BIOMED

Seattle BioMed is the largest, independent, non-profit research institute in the U.S. focused solely on the world's most devastating infectious diseases. More than 300 strong, we are dedicated to reducing human suffering and saving lives by converting knowledge into solutions.

Our research is the foundation for new vaccines, drugs and diagnostics that will benefit those who need our help most: the 14 million who will otherwise die each year from infectious diseases.

DISEASE FOCUS

Emerging Infections & TB

- Tuberculosis
- Yeast and mold infections

HIV/AIDS

Malaria

Trypanosomatids

- African sleeping sickness
- Chagas' disease
- Leishmaniasis
- Toxoplasmosis



307 Westlake Avenue North, Suite 500
Seattle, Washington 98109-5219 USA
Phone: 206.256.7200
Fax: 206.256.7229
seattlebiomed.org